CEO Geoffrey Dow adds 7,350 SXTP shares in open-market buy

Rhea-AI Filing Summary

60 DEGREES PHARMACEUTICALS, INC. President and CEO Geoffrey S. Dow reported an open-market purchase of Common Stock. On June 12, 2026, he bought 7,350 shares at an average price of $1.3784 per share. After this transaction, he directly owns 24,131 shares of the company’s Common Stock.

Insider Trade Summary

Net Buyer: 7,350 shares ($10,131)

Net Buy 1 txn

Insider DOW GEOFFREY S

Role President and CEO

Bought 7,350 shs ($10K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	7,350	$1.3784	$10K

Holdings After Transaction: Common Stock — 24,131 shares (Direct, null)

Footnotes (1)

Key Figures

Shares purchased: 7,350 shares Purchase price: $1.3784 per share Shares owned after: 24,131 shares +2 more

5 metrics

Shares purchased 7,350 shares Open-market purchase of Common Stock on June 12, 2026

Purchase price $1.3784 per share Average price for the 7,350-share buy

Shares owned after 24,131 shares Total direct Common Stock holdings after transaction

Net buy shares 7,350 shares Net buy direction in this Form 4

Buy transactions 1 Number of buy transactions reported

Key Terms

open-market purchase, Common Stock, Form 4, net-buy

4 terms

open-market purchase financial

"transaction_action: "open-market purchase" for the Common Stock transaction"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

Common Stock financial

"security_title: "Common Stock" for the reported transaction"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"INSIDER FILING DATA (Form 4) for Geoffrey S. Dow"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

net-buy financial

"transactionSummary shows netBuySellDirection as "net-buy""

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DOW GEOFFREY S

(Last) (First) (Middle)

C/O 60 DEGREES PHARMACEUTICALS, INC.

1025 CONNECTICUT AVENUE NW SUITE 1000

(Street)

WASHINGTON DISTRICT OF COLUMBIA 20036

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
60 DEGREES PHARMACEUTICALS, INC. [ SXTP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/12/2026		P		7,350	A	$1.3784	24,131	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Geoffrey Dow	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did 60 DEGREES PHARMACEUTICALS (SXTP) report?

60 DEGREES PHARMACEUTICALS reported an insider open-market stock purchase. President and CEO Geoffrey S. Dow bought 7,350 shares of Common Stock, increasing his direct ownership stake as disclosed in the Form 4 filing.

How many SXTP shares did Geoffrey S. Dow buy and at what price?

Geoffrey S. Dow bought 7,350 shares of SXTP Common Stock. The Form 4 shows an average purchase price of $1.3784 per share in an open-market transaction dated June 12, 2026.

What is Geoffrey S. Dow’s total SXTP shareholding after this Form 4?

After the reported purchase, Geoffrey S. Dow directly owns 24,131 shares of 60 DEGREES PHARMACEUTICALS Common Stock. This total reflects his position immediately following the 7,350-share open-market acquisition.

Was the SXTP insider transaction a purchase or sale of shares?

The SXTP insider transaction was a purchase. The Form 4 lists transaction code P and describes it as an open-market purchase of 7,350 shares of Common Stock by President and CEO Geoffrey S. Dow.

Does the SXTP Form 4 show any insider stock sales or only purchases?

The Form 4 for 60 DEGREES PHARMACEUTICALS shows only a purchase transaction. It reports one open-market buy of 7,350 shares by Geoffrey S. Dow and no insider stock sales in this filing.